Phase II trial

Biotechnology company Sensorion has enrolled the first patient in its Phase IIa Proof of Concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity.  Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity, or permanent and irreversible hearing loss, which occurs […]

Beckley Psytech has initiated a Phase IIa study investigating BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for treatment resistant depression (TRD).  Depression affects around 280 million people around the world, but 30% of those living with the condition are resistant to available antidepressant medications, meaning there is an urgent need for more […]

Biopharmaceutical company Rezolute has initiated a Phase II proof-of-concept study for RZ402, a plasma kallikrein inhibitor (PKI) being developed as an oral therapy for the treatment of diabetic macular oedema (DMO).   The current standard of care for DMO is anti-vascular growth factor (anti-VEGF) injections into the eye, requiring repeated administration over recurring periods of time […]

A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK under a new agreement.  The Phase IIb LIBERATE study will test the tolerance and the efficacy of glenzocimab 1000mg to reduce heart damage following a myocardial infarction (MI). According to the partnership between the University of […]

A first-in-class investigational antitubercular agent has shown early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.  The Phase IIa study evaluated GSK’s GSK3036656 in participants with drug-susceptible pulmonary tuberculosis. The company hopes GSK3036656 could be a component of simpler treatment regimens in the future which could help address the TB […]

BioSenic’s arsenic trioxide (ATO) autoimmune disease platform has completed a successful Phase IIb trial in chronic Graft vs Host Disease (cGVHD) and is preparing to move to a Phase III trial.  The BioSenic autoimmune platform was created by Medsenic to target systemic autoimmune diseases using ATO as an active anti-inflammatory and immunomodulatory agent.  The Phase […]

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa.   The antibody was up to 88.2% effective at preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody can prevent malaria infection in an endemic region.  The […]